Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Dr Katrin Kramer

PositionResearch Fellow
DepartmentDepartment of Pathology (DSM)
QualificationsBSc PhD
Research summaryImmune therapies for cancer

Research

My research interest focusses on the development of cancer immunotherapies. I am especially interested in understanding how the delivery form of immunotherapies influences their efficacy and how novel therapies can be combined to induce an effective anti-cancer immune response.

During my PhD at the School of Pharmacy, University of Otago, I worked on generating and comparing different linking mechanisms between cancer antigen and vaccine adjuvants and how they influence the generation of anti-tumour immune responses. My current project as a Postdoctoral Fellow in the Department of Pathology focuses on developing an immunotherapy for breast cancer. For this I use virus-like particles (VLP) delivering tumour antigens in order to prime immune cells to selectively recognise and destroy cancer cells while sparing healthy cells. Furthermore I work on understanding how successful immunotherapies are in a diverse patient population and whether specific patient groups benefit from different treatment combinations.

Publications

Kramer, K., Al-Barwani, F., Baird, M. A., Young, V. L., Larsen, D. S., Ward, V. K., & Young, S. L. (2019). Functionalisation of virus-like particles enhances antitumour immune responses. Journal of Immunology Research, 2019, 5364632. doi: 10.1155/2019/5364632

Kramer, K., Young, S. L., & Walker, G. F. (2019). Data on the uptake of reducible antigen-adjuvant conjugates by dendritic cells [Data article]. Data in Brief. Advance online publication. doi: 10.1016/j.dib.2019.103759

Kramer, K., Shields, N. J., Poppe, V., Young, S. L., & Walker, G. F. (2017). Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity. Molecular Therapy, 25(1), 62-70. doi: 10.1016/j.ymthe.2016.10.001

Grant, M. L., Shields, N., Neumann, S., Kramer, K., Bonato, A., Jackson, C., Baird, M. A., & Young, S. L. (2017). Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells. Clinical & Translational Immunology, 6(7), e149. doi: 10.1038/cti.2017.28

Kramer, K., Young, S. L., & Walker, G. F. (2017). Comparative study of 5′- and 3′-linked CpG–antigen conjugates for the induction of cellular immune responses. ACS Omega, 2(1), 227-235. doi: 10.1021/acsomega.6b00368

Journal - Research Article

Kramer, K., Al-Barwani, F., Baird, M. A., Young, V. L., Larsen, D. S., Ward, V. K., & Young, S. L. (2019). Functionalisation of virus-like particles enhances antitumour immune responses. Journal of Immunology Research, 2019, 5364632. doi: 10.1155/2019/5364632

Kramer, K., Shields, N. J., Poppe, V., Young, S. L., & Walker, G. F. (2017). Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity. Molecular Therapy, 25(1), 62-70. doi: 10.1016/j.ymthe.2016.10.001

Kramer, K., Young, S. L., & Walker, G. F. (2017). Comparative study of 5′- and 3′-linked CpG–antigen conjugates for the induction of cellular immune responses. ACS Omega, 2(1), 227-235. doi: 10.1021/acsomega.6b00368

Grant, M. L., Shields, N., Neumann, S., Kramer, K., Bonato, A., Jackson, C., Baird, M. A., & Young, S. L. (2017). Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells. Clinical & Translational Immunology, 6(7), e149. doi: 10.1038/cti.2017.28

^ Top of page

Journal - Research Other

Kramer, K., Young, S. L., & Walker, G. F. (2019). Data on the uptake of reducible antigen-adjuvant conjugates by dendritic cells [Data article]. Data in Brief. Advance online publication. doi: 10.1016/j.dib.2019.103759

More publications...